Asia-Pacific Exosome Therapeutic Market By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research & Academic Institutes), Country (South Korea, Australia, Hong Kong), Market Trends and Forecast to 2026
Market Analysis and Insights: Asia-Pacific Exosome Therapeutic Market
Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a stronger CAGR of 20.1% in the forecast period of 2019 to 2026 and expected to reach USD 8,492.80 million by 2026 from USD 1,957.80 million in 2018. Increasing research and development activities in exosome therapeutics pharmaceutical companies is the factors for the market growth.
Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.
Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving approval for clinical trial for exosome therapeutic. For instance, In July 2019, Exopharm has received approval for first-in-human clinical trial for Plexaris from Melbourne Health Human Research Ethics Committee to commence the PLEXOVAL wound healing study. Plexaris is a new exosome product which is sourced from human blood platelets and has been purified by using LEAP Technology. The approval for clinical trial will help the company to launch product in future.
Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in Asia-Pacific exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further expected creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2026.
This exosome therapeutics market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Exosome therapeutic Market Scope and Market Size
Asia-Pacific exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes therapeutics provides better alternative solutions in treatment of chronic disease as well as less side effect compare than hybrid exosomes therapeutics.
Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells segment is dominating the market because it is most popular stem cell type which is better treatment option in case of bone and cartilage disease.
Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because rising number of cancer cases so chemotherapy act as potential treatment for cancer because it is minimize the size of tumors.
Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules is dominating in the market because its long blood circulation time and targeting ability, better stability, safety and ease of manufacture compare than small molecules.
Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology is dominating in the market because increasing incidence of cancers in the Asia-Pacific. As per the National Centre Biotechnology Institute in 2050, estimated 7.8 million new cancer cases arise.
Based on route of administration, the market is segmented into oral and parenteral. Parenteral route of administration is dominating in the market because it is provide multiple advantages such fast absorption, no need metabolism as well as less side effect compare than oral route.
The Asia-Pacific exosome therapeutic market is also segmented on the basis of end user. The Exosome Therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes and others. Hospitals provide better treatment facilities as well as well as skilled staffs are availability in the hospitals. For instance China has increased significantly hospitals over the last decades. In 2017, around 2,451 hospitals are present in China.
Exosome therapeutic Market Country Level Analysis
The Asia-Pacific exosome therapeutic market is analysed and market size information is provided by country type, source, therapy, transporting capacity, application, route of administration and end user.
The countries covered in the Asia-Pacific exosome therapeutic market report are South Korea, Australia, and Hong Kong.
South Korea dominates the Asia-pacific exosome therapeutics market due to strong manufacturing base as well as export of components required for exosome therapeutics, while the Hong Kong is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increased consumption by population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strong Investment in Research and Development Activities and New Technology Penetration
Asia-Pacific exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutics sales, components sales, impact of technological development in batteries and changes in regulatory scenarios with their support for the exosome therapeutics market. The data is available for historic period 2010 to 2017.
Competitive Landscape and Exosome Therapeutic Market Share Analysis
Asia-Pacific exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Asia-Pacific exosome therapeutics market.
The major players covered in the report are EXOCOBIO, Exopharm, Inc., Boehringer Ingelheim International GmbH, Avalon Globocare Corp., among other players in Asia-Pacific. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
- In October, Avalon GloboCare Corp. has collaborated with Weill Cornell Medicine to form standards in cGMP-grade for human endothelial cells sourced exosome which is significant for organ regeneration and vascular health and isolation and identification of exosomes sourced from tissue for liquid biopsy and clinical use. The collaboration will help the company to lead market as exosome isolation system as will be first in the world for standardization processing of cGMP-grade exosomes for clinical studies.
- In September, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series A funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.
Partnership, expansion and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeuticss through expanded model range.
Customization Available : Asia-Pacific Exosome Therapeutic Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), product under development data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.